MARIA A. VIVIANI, M.D.; ANNA M. TORTORANO, Ph.D.; PAOLO CARBONERA GIANI, M.D.; CLAUDIO ARICI, M.D.; ANTONIO GOGLIO, M.D.; PAOLO CROCCHIOLO, M.D.; MAURO ALMAVIVA, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Relapses of cryptococcal infection in patients with the acquired immunodeficiency syndrome (AIDS) have been reported frequently, and need of a long-term antifungal therapy is evident (1-3). The new triazole derivative, itraconazole (Janssen Pharmaceutica Beerse, Belgium), seems to be a promising drug for this purpose, as documented by our first results in the treatment of disseminated cryptococcosis in three patients with AIDS (4).
All the patients were at first given the conventional therapy and had marked improvement, but treatment was discontinued after 20 to 45 days because of intolerance or toxicity in two patients and because of the
VIVIANI MA, TORTORANO AM, GIANI PC, et al. Itraconazole for Cryptococcal Infection in the Acquired Immunodeficiency Syndrome. Ann Intern Med. 1987;106:166. doi: https://doi.org/10.7326/0003-4819-106-1-166_1
Download citation file:
Published: Ann Intern Med. 1987;106(1):166.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use